JMKX000197 / Jemincare - LARVOL DELTA

A STING agonist, JMKX000197, for the treatment of malignant pleural effusion in patients with advanced solid tumors: preliminary results of the dose escalation phase in a prospective multicenter Phase I trial [WITHDRAWN] (ESMO 2025) - No abstract available

Clinical • Metastases • P1 data • Pleural effusion • Oncology • Solid Tumor

A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Jemincare | Not yet recruiting ➔ Recruiting

Enrollment open • Respiratory Diseases

A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Jemincare

New P1 trial • Respiratory Diseases

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs (BioSpace) - "On November 28, NMPA has approved a clinical trial for JMKX003948 to treat renal cell carcinoma....On December 12, FDA has approved a clinical trial for JMKX000197 to treat BCG-unresponsive non-muscle-invasive bladder cancer, and earlier on October 19, NMPA has approved the clinical trial."

IND • New trial • Bladder Cancer • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Jemincare

New P1 trial • Respiratory Diseases • IL6